Integrated Drug Product and Device Capability and Innovations Providing High-Dose Delivery Solutions

Get actionable insights into accelerated drug product development, optimized manufacturing processes for viscosities ≤50 cP, and commercial viability for next-generation biologics.

Register Free: https://www.biopharminternational.com/bp_w/device-capability

Event Overview:

The biopharmaceutical industry’s shift toward patient-centric, high-dose therapies, which is based on a growing demand for subcutaneous (SC) administration, requires innovative approaches to overcome technical barriers. This webinar discusses 3 integrated strategies to achieve high-dose delivery:

• A technology platform for high-concentration formulation development: WuXiHigh™ 2.0;
• Coformulation technology that enables large-volume SC administration; and
• Device-enabled solutions.

Attendees can expect actionable insights into accelerated drug product development, optimized manufacturing processes for viscosities ≤50 cP, and commercial viability for next-generation biologics.

Key Learning Objectives:

• Understand how high-throughput screening cuts drug product development time and cost.
• Master viscosity-reducing technologies to enable stable and deliverable drugs.
• Learn about a scalable manufacturing process for high-viscosity biologics.
• Explore the cutting-edge technology that enables large-volume SC administration.

Who Should Attend:

• Formulation scientists facing high-concentration and high-viscosity challenges
• CMC leaders needing a scalable process for high-dose SC biologics
• Biopharmaceutical and biotechnology executives seeking a faster timeline and lower cost

Featured Speaker:

Jeremy Guo, PhD

Senior Vice President and Head of
Drug Product Development and Clinical Drug Product Manufacturing
WuXi Biologics

Jeremy Guo, PhD, is senior vice president and the head of drug product development and clinical drug product manufacturing at WuXi Biologics. He has over 20 years of industry experience in formulation, process, and device development for biologics covering a wide range of modalities, including recombinant proteins, at Amgen, Regeneron, and Pfizer. Guo received his PhD from the University of Utah and his BS from the University of Colorado.

Dr. Guo led his team to equip global partners with preclinical, clinical, and commercial drug product development and manufacturing for a wide range of modalities, including monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, recombinant proteins, and enzymes. They also develop special preparations, such as high-concentration protein preparations, coprescription preparations, peptide preparations, nanoparticle preparations, and vaccines.

Speaker's Email: jeremy_guo@wuxibiologics.com
Speaker's LinkedIn: https://www.linkedin.com/in/jeremy-guo-0164821/

Register Free: https://www.biopharminternational.com/bp_w/device-capability